Search
Benzyl alcohol
go.drugbank.com/drugs/DB06770ApprovedInvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesDalteparin
go.drugbank.com/drugs/DB06779ApprovedInvestigationalDalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains ...
Products: P, FRAGMIN PCarbomycin
go.drugbank.com/drugs/DB11383ExperimentalVet approvedCarbomycin, also called magnamycin, is crystalline macrolide antibiotic. This antibacterial is obtained from Streptomyces halstedii and it presents a large inhibitory effect against Gram-positive bacteria and some Mycoplasma strains. The...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsEprinomectin
go.drugbank.com/drugs/DB11405ExperimentalVet approvedCategories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsSalinomycin
go.drugbank.com/drugs/DB11544ExperimentalVet approvedCategories: P-glycoprotein inhibitorsLesinurad
go.drugbank.com/drugs/DB11560ApprovedWithdrawnLesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptak...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersInsulin tregopil
go.drugbank.com/drugs/DB11568InvestigationalCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersRupatadine
go.drugbank.com/drugs/DB11614ApprovedInvestigationalRupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesTucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalTucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tuca...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsBryostatin 1
go.drugbank.com/drugs/DB11752InvestigationalBryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors